|
Oncology Drug Development in
Practice
(ODDP 2014)
Amsterdam, The Netherlands,
November 26-28, 2014
ONLY 6 PLACES LEFT IN 2014
COURSE
Act now to secure your place in this year’s course!
The next course will only be given in late 2015.
ODDP 2014 is a training program that
teaches knowledge and skills needed by corporate an academic professionals in
oncology drug development. The program is particularly useful for those looking
for an introduction into oncology and anticancer drug development, the latter in particular in Europe. This is the continuation of a highly successful international educational program offered annually as of 2004.
Educational profile
ODDP 2014 will cover the anticancer drug development process as well as general aspects of (medical and hematological) oncology and strategic and regulatory issues in the development of cancer therapeutics:
- Part A: General introductions: tumor biology, pathology, medical oncology, hemato-oncology (day 1)
- Part B: Drug development environment, preclinical, early clinical and late-phase development, post-registration studies (days 2 and 3)
Confirmed Faculty:
Experts from leading
academic research institutes and oncology-orientated companies, having
expertise and hands-on experience in cancer research, clinical oncology, or
anticancer drug development:
- Rob Berg, Medical Director Oncology, INC Research, Utrecht, The Netherlands (course chairman)
- Ferry Eskens, Medical Oncologist, Erasmus Medical Center, Rotterdam, The Netherlands
- Remond Fijneman, Geneticist, VU University Medical Center, Amsterdam, The Netherlands
- Adriaan Fruijtier, Director, Regulatory Affairs, CATS Consultants, Dietmannsried, Germany
- Winald Gerritsen, Professor in Tumor Immunotherapy, Radboud University Medical Centre, Nijmegen, The Netherlands
- Eric Hoedemaker, Medical Director, Novartis Pharma, Arnhem, The Netherlands
- Marie José Kersten, Hematologist, Academic Medical Center, Amsterdam, The Netherlands
- Marinus Lobbezoo, Senior Biomedical Consultant, Congress by design, Harmelen, The Netherlands (course chairman)
-
Martijn Lolkema, Medical Oncologist,
Erasmus Medical Center, The Netherlands
- Ton Logtenberg, Chief Executive Officer, Merus, Utrecht, The Netherlands
- Kees Melief, Professor of Immunohematology, Leiden University Medical Center, Leiden, The Netherlands
- Alain van Gool, Professor and Head Radboud Center for Proteomics, Glycomics & Metabolomics, Radboud University Medical Center, Nijmegen, The Netherlands
- Kate Owen, Medicine and Science Director, AstraZeneca, Macclesfield, Cheshire, UK
- Eric van der Putten, Oncology Drug Development Expert, Leiderdorp, The Netherlands (also course chairman)
- Paul van Diest, Professor of Pathology, University Medical Center, Utrecht, The Netherlands
- Jan Vermorken, Professor of Medical Oncology, Antwerp University, Edegem, Belgium
- Geraldine Vink, Senior Medical Advisor Oncology, Amgen, Breda, The Netherlands
- Wouter Wijker, Biostatistician, Auxiliis Clinical Development, Budapest, Hungary
Register now:
A maximum of 25
participants will be accepted and only 6 places are left. Immediate registration is
therefore strongly recommended if you don’t want to wait another year.
|
Download the
flyer
Amsterdam
![]()
Mercure Hotel
Amsterdam City
![]()
|